WBC100

N/A

Report date: 2026/02/18 20:02:09
NME

Base Information

Drug NameWBC100
Drug Alias NameWBC100WBC-100
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMyc proto-oncogene protein inhibitors
TargetsMyc proto-oncogene protein
Therapy Area/IndicationsSolid tumoursHematologic NeoplasmsLeukemia, Myeloid, Acute +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesHangzhou Weben Pharmaceutical Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesHangzhou Weben Pharmaceutical Co Ltd
Inactive CompaniesZhejiang University
Active IndicationsHematologic NeoplasmsLeukemia, Myeloid, Acute
Inactive IndicationsSolid tumoursNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A